Evaluation of cryopreservation techniques for goat embryos

International audienc

Desarrollo embrionario en los caprinos: estudio de las condiciones de cultivo

peer reviewedThree culture Media: PBS; HAM F10 and B2 Menezo were used to compare and study the in vitro development of goats embryos. After 48h of culture in these media, the rate of Morulas developed was o%, 19% and 42% respectively, and that of blastocysts was 25%, 73% and 95%. The B2 Menezo medium would therefore appear well adapted to the culture of blastocysts. The morulas, however, irrespective of the medium used showed limited development.Trois milieux de culture: PBS, HAM F10 et B2 Menezo sont comparés pour étudier le développement in vitro de l'embryon caprin. Après 48 heures de culture dans ces milieux, le taux de développement des morulas est, respectivement, de 0%, 19% et 42% et celui des blastocystes de 25%, 73% et 95%. Le milieu B2 Menezo semble donc bien adapté à la culture des blastocystes. Par contre les morulas caprines présentent, quel que soit le milieu utilisé un développement réduit.Tres medias de cultivo: PBS, HAM F10 y Menezo son comparados para estudiar in vitro le desarrollo del embrion caprino. Luego de 48h de cultivos en esos medios, el nivel de desarrollo de las morulas es, respectivamente, de 0% et de 42% y el desarrollo de blastocistos de 25%, 73% y 95% El medio Menezo parece por lo tanto bien adaptado al cultivo de los blastocistos. Por el contrario las morulas caprinas presentan, sea cual sea el medio utilizado un desarrollo reducido

La inseminaciõn artificial intra-uterina transperitoneal en la cabra. 2. Estudio comparativo de la tasa de fecudaciõn artificial intra-uterine

peer reviewedThis study was carried out on 570 ovocytes. It shows that goats suprovulated due to FSH treatements of 16 mg Armour given over 3 days (in 8-4-4 mg/day) or 21 mg Armour over 4 days (in 7-6-4-4 mg/day) and undergoing a single intra-uterine transperitoneal insemination under endoscopic control, carried out 46h39 after removing the sponges gives a satisfactory rate of fecondation close to 70%. This rate is a more 15 points lower than that obtained by 2 successive matings 12 hours apart (36 and 24 hours after removing the sponges). An FSH treatment of 21 mg Armour over a three day period (mg/day:11,5,5) only gives a fecundity rate of 19,5% in intra-uterine and 56.58 % after mating. This gives a global fecundity rate for all treatments of 50.77% and 80.44% for A.I. through intra-uterine method and mating.Cette étude portant sur 570 ovocytes montre que chez des chèvres superovulées avec des traitements FSH de 16mg Armour administrés sur 3 jours (en mg/J:8-4-4) ou de 21 mg Armour sur 4 jours (en mg/J:7-6-4-4) une seule insémination intra-utérine, transpéritonéale, sous contrôle endoscopique, réalisée, en moyenne 46h39 après le retrait des éponges, permet d'obtenir un taux de fécondité satisfaisant, voisin de 70 p.cent. Celui-ci n'est inférieur que de 15 points à celui obtenu, avec les mêmes traitements, après deux saillies réalisées à douze heures d'intervalle (36 et 48 h après le retrait des éponges). Par contre l'utilisation d'un traitement FSH de 21 mg Armour administré sur 3 jours (en mg/J:11-5-5) ne permet que 19,5 p. cent de fécondité par voie intra-utéine et 56,58 p. cent après saillie. Soit tout traitement confondu une fécondité de 50,77 p. cent et de 80,44 p. cent respectivement pour l'insémination artificielle par la voie intra-utérine et la saillie.Este estudio realizado a partir de 570 ovocitos, muestra que en cabras con superovulacion por medio de tratamientos de FSH en dosis de 16mg distribuidos en 3 dias (8,4,4 mg/dia) o de 21mg, en 4 dias (7,6,4,4 mg/dia), una sola insemincacion artificial intra-uterina, transperitoneal, bajo control endoscopico, efectuada 45 horas luego de haber retirado las esponjas, permitte obtener una tasa de fecundacion cercada al 70%. Efectivamente, esta es inferior de solamente 15 puntos al resultado obtenido luego de dos montas efectuadas a doce horas de intervalo (36 y 48 horas depues de haber retirado de las esponjas). Por el contrario la utilizacion de un tratmiento de FSH de 21 mg Armour administrado en 3 dias (en mg/dia 11-5-5) no permite que 19,5 p. cent de feculdidad por via intra-uterina y de 56,58 p. cent despues de la monta. Luego todo tratamiento da una fecundidad de 50,77 p. cent y de 80,44 p. cent respectivamente por via intra-uterina y por monta

Comparison of the efficiency of three cryoprotectants for freezing goat embryos.

editorial reviewe

VAS e governo del territorio: considerazioni e suggerimenti per la revisione della parte II del D.lgs 152/2006

Commenti e suggerimenti all'applicazione della Direttiva Europea sulla valutazione ambientale strategica (VAS) nella legislazione nazionale e regionale

A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the ?BRAF BeCool? study

background: despite the well-known negative prognostic value of the (V600E) BRAF mutation in patients with metastatic colorectal cancer (mCRC), its outcome is quite heterogeneous, and the basis for this prognostic heterogeneity should be better defined.methods: two large retrospective series of (V600E) BRAF-mutated mCRC from 22 institutions served as an exploratory and validation set to develop a prognostic score. the model was internally and externally validated. results: a total of 395 (V600E) BRAF-mutated mCRCs were included in the exploratory set. performance status, CA19.9, lactate dehydrogenase, neutrophil/lymphocyte ratio, grading and liver, lung and nodal involvement emerged as independent prognostic factors for overall survival (OS). two different scoring systems were built: a 'complete' score (0-16) including all significant covariates and a 'simplified' score (0-9), based only on clinicopathological covariates, and excluding laboratory values. adopting the complete score, proportions of patients with a low (0-4), intermediate (5-8) and high (9-16) score were 44.7%, 42.6% and 12.6%, respectively. the median OS was 29.6, 15.5 (hazard ratio [HR] for intermediate vs low risk: 2.16, 95% confidence interval [CI]: 1.44-3.22, p < .001) and 6.6 months (HR for high vs low risk: 4.72, 95% CI: 2.72-8.20, p < .001). similar results were observed also after adjusting for the type of first-line treatment and adopting the simplified score. the simplified prognostic score derived from the exploratory set was then applied to the validation set for external confirmation. conclusions: these scoring systems are based on easy-to-collect data and defined specific subgroups with relevant differences in their life expectancy. these tools could be useful in clinical practice, would allow better stratification of patients in clinical trials and may be adopted for proper adjustments in exploratory translational analyses. (C) 2019 elsevier ltd. all rights reserved

Notes On The Status Of Viola Uliginosa In Lithuania

BACKGROUND: Despite the well-known negative prognostic value of the V600EBRAF mutation in patients with metastatic colorectal cancer (mCRC), its outcome is quite heterogeneous, and the basis for this prognostic heterogeneity should be better defined. METHODS: Two large retrospective series of V600EBRAF-mutated mCRC from 22 institutions served as an exploratory and validation set to develop a prognostic score. The model was internally and externally validated. RESULTS: A total of 395 V600EBRAF-mutated mCRCs were included in the exploratory set. Performance status, CA19.9, lactate dehydrogenase, neutrophil/lymphocyte ratio, grading and liver, lung and nodal involvement emerged as independent prognostic factors for overall survival (OS). Two different scoring systems were built: a 'complete' score (0-16) including all significant covariates and a 'simplified' score (0-9), based only on clinicopathological covariates, and excluding laboratory values. Adopting the complete score, proportions of patients with a low (0-4), intermediate (5-8) and high (9-16) score were 44.7%, 42.6% and 12.6%, respectively. The median OS was 29.6, 15.5 (hazard ratio [HR] for intermediate vs low risk: 2.16, 95% confidence interval [CI]: 1.44-3.22, p < .001) and 6.6 months (HR for high vs low risk: 4.72, 95% CI: 2.72-8.20, p < .001). Similar results were observed also after adjusting for the type of first-line treatment and adopting the simplified score. The simplified prognostic score derived from the exploratory set was then applied to the validation set for external confirmation. CONCLUSIONS: These scoring systems are based on easy-to-collect data and defined specific subgroups with relevant differences in their life expectancy. These tools could be useful in clinical practice, would allow better stratification of patients in clinical trials and may be adopted for proper adjustments in exploratory translational analyses